News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
[Republican Politics and Wall Street] Douglas Rissing Shares of Lenz Therapeutics (LENZ [https://seekingalpha.com/symbol/LENZ]) slipped for the third consecutive session on Thursday after Bank of America downgraded the eye drug developer to Neutral from Buy, citing a slower-than-expected rollout of its presbyopia therapy VIZZ. In …
Lenz Therapeutics' stock fell for the third straight day after Bank of America downgraded the company from Buy to Neutral. The downgrade was attributed to a slower-than-expected launch of its presbyopia therapy, VIZZ. Analyst Jason Gerberry also lowered his price target for LENZ.
BofA Securities downgraded LENZ Therapeutics Inc. (NASDAQ:LENZ) from Buy to Neutral and cut its price target significantly, citing a slower-than-expected launch of its VIZZ presbyopia eye drops. Despite some positive financial results in Q2 2026, including a revenue beat, the firm expressed concerns about …
Analysts have revised the average 12-month price target for LENZ Therapeutics, Inc. (LENZ) stock down to $29.86 from $32, with individual forecasts ranging from $7 to $60 per share. Despite the cut, this new target still suggests a substantial 473% potential upside from its …
LENZ Therapeutics (NASDAQ:LENZ) reported its quarterly earnings, beating analyst estimates by $0.03 EPS with a loss of $1.02 per share and revenue of $5.49 million, significantly exceeding expectations. Despite commercial momentum and increased prescription sales, the company posted a $31.9 million net loss, and …
LENZ Therapeutics exceeded Q2 2026 financial forecasts, reporting a narrower loss of $1.02 per share and revenue of $5.5 million, significantly beating analyst expectations. The positive results were driven by strong early adoption of its presbyopia eye drop, VIZZ, including a 45% month-over-month increase …
LENZ Therapeutics reported a Q2 2026 net loss of $31.9 million despite generating $5.5 million in total revenue, driven by VIZZ product sales and ex-U.S. licensing agreements. The company's net loss was primarily due to increased selling, general, and administrative expenses as it expanded …
LENZ Therapeutics reported strong Q2 2026 financial results with $5.5 million in total revenue from VIZZ product sales and global license agreements. The company highlighted accelerating VIZZ prescription growth through its new telehealth channel and strong patient persistence, with over 60% of ePharmacy patients …
This article first appeared on GuruFocus. Revenue: Modestly lower than H1 2025, held close to prior-year levels amid a strong comparison base and deliberate pruning of low-margin volumes. EBITDA: Grew approximately 9% year-on-year, supported by pricing initiatives and cost measures. Operational EBITDA (Q2 2026): …
LENZ Therapeutics (Nasdaq: LENZ) is set to report its Q2 2026 earnings on August 11th, with investors keenly focused on the commercial success of its presbyopia eye-drop, VIZZ (LNZ100). The company's stock has significantly underperformed the broader market, dropping around 83% over the past …
LENZ Therapeutics announced it will host a webcast on August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights. The company is focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye …
LENZ Therapeutics announced it will host a webcast on August 11, 2026, to discuss its second-quarter 2026 financial results and recent corporate highlights. The webcast will feature discussions on VIZZ® (aceclidine ophthalmologic solution) 1.44%, the company's FDA-approved eye drop for presbyopia. The announcement follows …
This article provides a comprehensive stock analysis and "TradingKey Stock Score" for LENZ Therapeutics Inc (LENZ). It highlights the company's strong fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The analysis also covers institutional ownership, analyst ratings, and …
This article details the shareholder structure of LENZ Therapeutics Inc (LENZ), listing its major shareholders and their proportions, such as RA Capital Management, LP (13.33%) and Fidelity Management & Research Company LLC (11.81%). It also categorizes shareholder types, including Investment Advisor (42.54%) and Venture …
This article provides a basic overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) on TradingView, focusing on accessing its financial data. It indicates the stock market status and directs users to various financial segments like statements, statistics, dividends, earnings, and segment performance. The content is …
LENZ Therapeutics reported Q1 2026 revenue of $1.9 million, primarily from VIZZ product sales, with over 46,000 prescriptions filled since launch. While new patient adoption is growing, it is below target, prompting expanded sales force and DTC campaigns. The company is actively pursuing international …
LENZ Therapeutics Inc. is a pre-commercial stage biopharmaceutical company focused on developing aceclidine-based eye drops for presbyopia. Their lead product, LNZ100, is a once-daily eye drop that was evaluated in a Phase III study. The article also lists company executives, their shareholdings, and institutional …
LENZ Therapeutics (LENZ) presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, highlighting the recent approval of its non-invasive ophthalmic drop for presbyopia, which uses aceclidine to restore near vision. The company's clinical trials demonstrated significant efficacy, with most patients achieving 20/40 vision …
LENZ Therapeutics presented at the 2024 Cantor Fitzgerald Global Healthcare Conference, highlighting its once-daily eye drop for presbyopia. The company completed Phase III studies, filed an NDA, and anticipates approval mid-next year for a launch in the second half of 2025. LENZ Therapeutics is …
LENZ Therapeutics, Inc. (LENZ) is projected to report a decline in Q2 earnings and revenues year-over-year, with an expected quarterly loss of $1.21 per share and revenues of $2.21 million. Despite a recent upward revision in EPS estimates, the company's Earnings ESP of -8.04% …
LENZ Therapeutics (LENZ) has released a summary of its proxy filing, detailing plans for its virtual annual meeting on June 12, 2026. Stockholders will vote on electing three Class II directors and ratifying Ernst & Young LLP as the independent auditor for 2026. The …
LENZ Therapeutics (NASDAQ:LENZ) had US$258m in cash by March 2026 and burned through US$87m in the last year, giving it a cash runway of about 3.0 years. While its cash burn increased significantly by 68% in the last year, analysts expect the company to …
Search by ticker symbol or company name and select a result to open its chart.